Enhancement of dissolution rate of piroxicam using liquisolid compacts
- PMID: 15848213
- DOI: 10.1016/j.farmac.2004.09.005
Enhancement of dissolution rate of piroxicam using liquisolid compacts
Abstract
Piroxicam is a poorly soluble, highly permeable drug and the rate of its oral absorption is often controlled by the dissolution rate in the gastrointestinal. The poor dissolution rate of water-insoluble drugs is still a major problem confronting the pharmaceutical industry. There are several techniques to enhance the dissolution of poorly soluble drugs. Among them, the technique of liquisolid compacts is a promising technique towards such a novel aim. In this study, the dissolution behaviour of piroxicam from liquisolid compacts was investigated in simulated gastric fluid (SGF, pH 1.2) and simulated intestinal fluid (SIF, pH 7.2). To this end, several liquisolid tablets formulations containing various ratios of drug:Tween 80 (ranging from 10% to 50% w/w) were prepared. The ratio of microcrystalline cellulose (carrier) to silica (coating powder material) was kept constant in all formulations. The results showed that liquisolid compacts demonstrated significantly higher drug release rates than those of conventionally made (capsules and directly compressed tablets containing micronized piroxicam). This was due to an increase in wetting properties and surface of drug available for dissolution.
Similar articles
-
The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts.J Pharm Pharm Sci. 2005 Jan 12;8(1):18-25. J Pharm Pharm Sci. 2005. PMID: 15946594
-
Effect of some commercial grades of microcrystalline cellulose on flowability, compressibility, and dissolution profile of piroxicam liquisolid compacts.Drug Dev Ind Pharm. 2009 Feb;35(2):243-51. doi: 10.1080/03639040802277672. Drug Dev Ind Pharm. 2009. PMID: 18785038
-
An investigation of physicochemical properties of piroxicam liquisolid compacts.Pharm Dev Technol. 2007;12(3):337-43. doi: 10.1080/10837450701247574. Pharm Dev Technol. 2007. PMID: 17613897
-
Liquisolid technology for dissolution rate enhancement or sustained release.Expert Opin Drug Deliv. 2010 Oct;7(10):1227-34. doi: 10.1517/17425247.2010.511173. Expert Opin Drug Deliv. 2010. PMID: 20731614 Review.
-
Drug release from liquisolid systems: speed it up, slow it down.Expert Opin Drug Deliv. 2011 Feb;8(2):191-205. doi: 10.1517/17425247.2011.548801. Epub 2011 Jan 12. Expert Opin Drug Deliv. 2011. PMID: 21222556 Review.
Cited by
-
Design and Characterization of Buccoadhesive Liquisolid System of an Antihypertensive Drug.J Drug Deliv. 2015;2015:574247. doi: 10.1155/2015/574247. Epub 2015 Oct 22. J Drug Deliv. 2015. PMID: 26579235 Free PMC article.
-
Polymeric surfactant based etodolac chewable tablets: formulation and in vivo evaluation.AAPS PharmSciTech. 2010 Dec;11(4):1730-7. doi: 10.1208/s12249-010-9548-z. Epub 2010 Dec 7. AAPS PharmSciTech. 2010. PMID: 21136309 Free PMC article.
-
Enhancement of the Oral Bioavailability of Fexofenadine Hydrochloride via Cremophor(®) El-Based Liquisolid Tablets.Adv Pharm Bull. 2015 Nov;5(4):569-81. doi: 10.15171/apb.2015.077. Epub 2015 Nov 30. Adv Pharm Bull. 2015. PMID: 26819931 Free PMC article.
-
Valsartan orodispersible tablets: formulation, in vitro/in vivo characterization.AAPS PharmSciTech. 2010 Mar;11(1):189-96. doi: 10.1208/s12249-009-9354-7. Epub 2010 Jan 29. AAPS PharmSciTech. 2010. PMID: 20112137 Free PMC article.
-
Piroxicam Loading onto Mesoporous Silicas by Supercritical CO2 Impregnation.Molecules. 2021 Apr 25;26(9):2500. doi: 10.3390/molecules26092500. Molecules. 2021. PMID: 33922927 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources